We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

STRATA Skin Sciences Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
4885
Market Cap
0.03M

Momentum Score

…

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.13
High
52 Week Price Range
0.00
Low
3.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

STRATA Skin Sciences is a small-cap medical technology company that develops devices for dermatologic conditions. Long-term growth drivers may include clinical adoption, expansion into new geographies and indications, and improved reimbursement, which could make the company appealing to investors seeking niche dermatology exposure.

Key risks include execution and go-to-market challenges, regulatory and reimbursement uncertainty, competition from larger device and pharmaceutical companies, and potential liquidity or financing constraints.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
30.70M
Revenue Per Share
6.60
Gross Profit TTM
17.88M
Debt / Equity
5.59
ROE
-158.91%
Net Debt
8.36M
ROCE
-113.49%
Diluted EPS TTM
-1.35

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.25M -10.26M -10.92M -5.49M -2.67M
Net income -6.26M -10.09M -10.83M -5.55M -2.71M
Selling general administrative 10.18M 11.30M 10.51M 10.09M 9.71M
Selling and marketing expenses 13.11M 12.29M 12.96M 15.30M 13.11M
Gross profit 17.88M 19.08M 18.46M 21.77M 19.85M
Reconciled depreciation 4.47M 5.31M 6.00M 5.69M 4.09M
Ebit -4.29M -8.15M -9.28M -4.56M -4.40M
Ebitda 0.18M -2.84M -3.38M 1.13M -0.30M
Depreciation and amortization 4.47M 5.31M 5.90M 5.69M 4.10M
Operating income -5.83M -9.26M -8.60M -4.56M -4.40M
Other operating expenses 36.53M 42.82M 41.96M 40.81M 34.38M
Interest expense 1.96M 2.11M 1.64M 0.93M 0.31M
Tax provision 0.01M -0.17M -0.09M 0.06M 0.03M
Interest income 0.41M 0.24M 0.19M 0.09M 0.01M
Net interest income -1.55M -1.86M -1.20M -0.84M -0.30M
Income tax expense 0.01M -0.17M -0.09M 0.06M 0.03M
Total revenue 30.70M 33.56M 33.36M 36.16M 29.98M
Total operating expenses 23.72M 28.34M 27.07M 26.42M 24.25M
Cost of revenue 12.81M 14.48M 14.90M 14.39M 10.13M
Total other income expense net -0.41M -1.00M -2.32M -0.93M 1.73M
Net income from continuing ops -6.26M -10.09M -7.20M -5.55M -2.71M
Net income applicable to common shares - - - - -2.71M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 30.52M 36.16M 42.02M 52.27M 46.59M
Intangible assets 3.38M 5.35M 7.32M 17.39M 10.08M
Other current assets 0.75M 1.83M 0.31M 0.69M 0.46M
Total liab 27.61M 31.18M 29.33M 30.44M 21.18M
Total stockholder equity 2.91M 4.97M 12.69M 21.83M 25.41M
Other current liab 6.16M 3.25M 6.36M 6.87M 6.38M
Common stock 0.01M 0.00M 0.04M 0.04M 0.03M
Capital stock 0.01M 0.00M 0.04M 0.04M 0.03M
Retained earnings -254.41M -248.14M -238.06M -227.23M -221.68M
Other liab - - - - 0.67M
Good will 1.43M 2.66M 6.52M 8.80M 8.80M
Other assets - - - - 0.22M
Cash 7.91M 7.26M 8.12M 5.43M 12.59M
Total current liabilities 26.74M 14.62M 12.17M 13.43M 12.80M
Current deferred revenue 2.25M 2.24M 2.12M 2.78M 3.29M
Net debt 8.36M 9.18M 7.51M 3.01M -4.56M
Short term debt 15.58M 0.33M 0.35M 0.35M 0.32M
Short long term debt 15.35M - - - -
Short long term debt total 16.27M 16.44M 15.63M 8.44M 8.03M
Other stockholder equity 257.31M 253.11M 250.71M 249.02M 247.06M
Property plant equipment - - - - 7.52M
Total current assets 15.60M 16.59M 15.54M 17.50M 19.97M
Net tangible assets - - - - 6.53M
Net receivables 4.12M 5.25M 4.44M 4.47M 3.43M
Long term debt - 15.19M 15.04M 7.48M 7.32M
Inventory 2.81M 2.25M 2.67M 5.55M 3.49M
Accounts payable 2.76M 2.43M 3.34M 3.42M 2.82M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 0.23M 0.23M 0.23M 0.10M 0.22M
Non current assets total 14.92M 19.56M 26.47M 34.77M 26.62M
Capital lease obligations 0.92M 1.25M 0.59M 0.96M 0.71M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -1.64M -4.68M -4.18M -7.13M
Change to liabilities - - - - -0.39M
Total cashflows from investing activities -1.47M -1.64M - - -7.13M
Net borrowings - 0.00M - - 0.23M
Total cash from financing activities 3.58M 1.93M 6.86M -0.50M 0.09M
Change to operating activities - - - - 1.25M
Net income -6.26M -10.09M -10.83M -5.55M -2.71M
Change in cash -0.68M 0.48M 1.32M -5.79M -5.53M
Begin period cash flow 8.60M 8.12M 6.79M 12.59M 18.11M
End period cash flow 7.91M 8.60M 8.12M 6.79M 12.59M
Total cash from operating activities -2.79M 0.19M -0.52M -1.11M 1.51M
Issuance of capital stock 3.58M 1.94M - - -
Depreciation 4.47M 5.31M 5.90M 5.69M 4.09M
Change to inventory -0.29M 0.57M 0.69M -1.52M -0.04M
Change to account receivables 1.00M -0.63M 0.14M -1.15M -0.49M
Other cashflows from financing activities 3.58M -0.02M -0.04M -0.50M 7.87M
Change to netincome - - - - -0.23M
Capital expenditures 1.47M 1.64M 5.02M 3.55M 3.65M
Change in working capital -0.89M 0.69M -0.07M -3.07M 0.32M
Stock based compensation 0.64M 0.43M 1.30M 1.47M 1.64M
Other non cash items -0.76M 4.04M 3.29M 0.32M -1.85M
Free cash flow -4.26M -1.45M -5.54M -4.66M -2.15M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SSKN
STRATA Skin Sciences Inc
-
-%
0.00 - 188.68 0.00 0.01 0.27 47.38
ABT
Abbott Laboratories
-0.71
0.65%
108.58 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
0.28
0.28%
101.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-2.16
0.68%
316.63 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
47.31 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

STRATA Skin Sciences Inc

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.

5 Walnut Grove Drive, Horsham, PA, United States, 19044

215 619 3200

114

Name Title Year Born
Mr. Nikolai Kabelev VP of R&D 1976
Mr. William D. Humphries M.B.A. Exec. Chairman 1966
Mr. Robert J. Moccia Pres, CEO & Director 1959
Mr. Christopher Lesovitz Chief Financial Officer 1982
Mr. Jay Sturm Gen. Counsel & Corp. Sec. 1956
Keith Simeone VP of Sales NA
Dr. Darrell S. Rigel Chief Medical Advisor 1951
Mr. Shmuel Gov Exec. VP & GM NA
Mr. Michael E. Goodman Head of International Sales NA
Mr. Michael R. Stewart Independent Consultant 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…